Global pharmaceutical firms are paying upfront to secure technology transfer deals with Alteogen, as demand for its subcutaneous injection platform surges; Shinhan Investment maintains a 730,000 won target price, citing strong licensing prospects despite recent patent litigation.
#YonhapInfomax #Alteogen #TechnologyTransfer #ShinhanInvestment #OptionAgreement #TargetPrice730000Won #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=97468
Global Pharma Firms Pay to Get in Line for Alteogen’s Technology—Target Price Set at 730,000 Won
Global pharmaceutical firms are paying upfront to secure technology transfer deals with Alteogen, as demand for its subcutaneous injection platform surges; Shinhan Investment maintains a 730,000 won target price, citing strong licensing prospects despite recent patent litigation.
Alteogen Inc. has named Jeon Tae-yeon as its new CEO, with founder Park Soon-jae stepping down from the chief executive role but remaining as board chairman, signaling a leadership transition at the South Korean biopharma firm.
#YonhapInfomax #Alteogen #JeonTaeYeon #ChiefExecutiveOfficer #ALTB4 #LeadershipTransition #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=97313
Alteogen Appoints Jeon Tae-yeon as New CEO—Chairman Park Soon-jae Steps Down
Alteogen Inc. has named Jeon Tae-yeon as its new CEO, with founder Park Soon-jae stepping down from the chief executive role but remaining as board chairman, signaling a leadership transition at the South Korean biopharma firm.
KOSDAQ Bellwether Alteogen Plunges 14% After 'Keytruda SC' Sales Ban in Germany
Alteogen shares plunged over 14% after a German court banned sales of partner Merck’s Keytruda SC, clouding royalty and milestone revenue prospects in Europe.
South Korea's KOSPI and KOSDAQ indices fell in early trading as investors awaited U.S. inflation data, with major stocks like SK hynix and Alteogen posting notable declines amid a lack of clear market drivers.
#YonhapInfomax #KOSPI #KOSDAQ #SKHynix #Alteogen #PCEPriceIndex #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=94098
KOSPI and KOSDAQ Decline in Absence of Market Catalysts
South Korea's KOSPI and KOSDAQ indices fell in early trading as investors awaited U.S. inflation data, with major stocks like SK hynix and Alteogen posting notable declines amid a lack of clear market drivers.
Alteogen Co. posted a 900% jump in Q3 revenue, driven by the commercialization of its ALT-B4 platform and milestone payments from FDA-approved Keytruda SC, marking a major turnaround in profitability and global expansion momentum.
#YonhapInfomax #Alteogen #ALTB4 #Q3Revenue #Keytruda #FDAApproval #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=90913
Alteogen Posts 900% Surge in Q3 Revenue as ALT-B4 Commercialization Accelerates
Alteogen Co. posted a 900% jump in Q3 revenue, driven by the commercialization of its ALT-B4 platform and milestone payments from FDA-approved Keytruda SC, marking a major turnaround in profitability and global expansion momentum.
South Korea's Kosdaq market sees biotech firms, propelled by special technology listings, dominate top market cap ranks, but tighter scrutiny after the Padu incident has raised entry barriers, fueling debate over adopting a Nasdaq-style "easy entry, fast exit" approach.
#YonhapInfomax #Kosdaq #Alteogen #SpecialListing #Biotech #MarketCapitalization #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=83122
Kosdaq Heavyweights Born from Tech Listing Exemptions—8 of Top 30 by Market Cap Are 'Special Listing Graduates' - Yonhap Infomax
South Korea's Kosdaq market sees biotech firms, propelled by special technology listings,
Yonhap Infomax News